News Focus
News Focus
Followers 59
Posts 7589
Boards Moderated 0
Alias Born 10/20/2014

Re: None

Monday, 01/22/2024 3:54:25 PM

Monday, January 22, 2024 3:54:25 PM

Post# of 447241
Back when I believed AMRN would be acquired by a BP,
I thought a BP acquirer would buy it to be the dominant leader
in the use of EPA...From today's PR it sounds as if the CEO
wants to place AMRN back on that track. Perhaps Denner's
intent may be what I envisioned long ago. Perhaps Denner
will want to sell AMRN on the basis that a BP could build on
what AMRN has already accomplished in order to make it
a leader regarding the use of EPA. Astra-Zenica may have
had a similar goal but got derailed because the combination
of EPA & DHA negated the many of the benefits conferred by
EPA by itself. At this stage AMRN is very cheap. My OPINION
remains that a BP could create peak revenues of over $2 billion
a year with Vascepa if they owned it. If Denner sees it the same
way then maybe he ultimately gets a BP to pony up an acceptable
BO price. (I still think something in the teens is doable...but the low
20's...Who knows!) Could be a 10-15X gain from here!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News